Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
OligoNucleotide Technologies for Rapid Advancement of Cancer Therapies (ON-TRACT)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom,Sweden,Belgium,Italy,France,Poland
Call: MSCA Doctoral Networks 2024 (HORIZON-MSCA-2024-DN-01, 2024)
Start date: 2026-01-01
End date: 2029-12-31
Duration (months): 48.0
Total project cost (EUR): 4432796.64
EU funding (EUR): 4432796.64
Participants: 16
Project status: SIGNED

ON-TRACT focuses on advancing oligonucleotides (ONs) in medicinal chemistry to tackle urgent challenges in treating lung cancer, B-cell malignancies, and chronic inflammation. ONs are powerful tools for gene-specific therapy, yet their clinical use is hindered by challenges such as limited stability, inefficient delivery, and off-target effects. Since 2000, more than a dozen Nobel Prizes related to oligonucleotides in Chemistry or Medicine/Physiology, such as CRISPR-CAS9, telomers, DNA replication, RNA vaccines or micro-RNAs, highlight their transformative potential, but further innovation is essential to realise their full impact. Our consortium, consisting of 10 academic research groups, 4 companies, 1 hospital, and 1 non-profit organisation, will address these limitations through an interdisciplinary approach. Key objectives include developing sustainable chemical synthesis methods to reduce environmental impact, advancing delivery technologies such as monoclonal antibodies, dendrimers, and inhalers for targeted and efficient delivery, and employing organoids as ethical, human-relevant alternatives to animal models for testing. By integrating expertise in chemistry, biology, advanced delivery systems and medicine, the project aims to create a robust framework for oligonucleotide-based therapies. This holistic strategy will not only advance the development of innovative treatments for severe diseases but also set new standards for sustainability and ethical testing in medicinal chemistry. In addition, we will train 13 highly skilled researchers, ready to take on Europe’s challenges in the life sciences sector; our interdisciplinary and intersectoral training programme will give all ON-TRACT researchers the skills needed for a successful career in any sector.

Keywords: dna chemistry,modified nucleotide,on therapy,targeted delivery,cancer gene silencing,imaging,delivery,chemoenzymatic synthesis,directed evolution,sustainable oligonucleotide synthesis
Holistic UGV-based Resilient and Real-time Intelligence for Crisis And Natural Emergency (HURRICANE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Disaster-Resilient Society for Europe
Action type: Research and Innovation actions
Countries involved: Italy,Spain,Portugal,France,Slovakia,Belgium,Netherlands
Call: Robotics: Autonomous or semi-autonomous UGV systems to supplement skills for use in hazardous environments (HORIZON-CL3-2023-DRS-01, 2023)
Start date: 2025-01-01
End date: 2028-12-31
Duration (months): 48.0
Total project cost (EUR): 3998202.5
EU funding (EUR): 3998202.5
Participants: 17
Project status: SIGNED

According to the World Meteorological Organization, the frequency of severe weather incidents has quintupled over the last five decades, causing more than 100 000 fatalities and 1.5 trillion euros of economic losses in Europe (EU). Consequently, disaster management capabilities need to be enhanced in this fast-evolving context. Robotics can play a crucial role to improve first responders’ safety and effectiveness in their operations. HURRICANE is a 15 partners multidisciplinary consortium aiming to overcome limitations that are still holding back these cutting-edge innovations from becoming a disaster management standard. HURRICANE will unlock the potential of UGV operation in hazardous environment, relying on enhanced vision capabilities and smart integration over a holistic, resilient and real-time situational awareness infrastructure that includes innovative UAV-UGV cooperation pathways (laser-based charging, UAV supporting UGV regarding route planning) and multi-technology communication infrastructure (5G, RF, optical wireless). Data-driven optimization models will provide recommendations through a user-friendly API to support FR’s tactics. Three complementary pilots will be implemented to demonstrate the benefits brought by HURRICANE solutions, in several challenging environments: peri-urban areas (Corsica), mountains (Alps) and wildfires (Andalusia). Last, but not least, EU-wide advanced training modules will be implemented to raise awareness among FR about these innovative technologies, integrating new operational procedures. At the end of the project, HURRICANE will show improved hazard management efficiency (60% operation time reduction, 95% false positive readout reduction), with reduced FR exposure to harmful situations, strengthened EU robotics industry leadership (5M€ of revenues and 50 jobs). In 2028, training will be provided for 100 FRs across 15 EU countries, aiming to achieve a total of 10,000 trained FRs by the year 2035.

Keywords: ugv uav communication optimization models photonics visualisation tools training
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONS (TRANSFORMER)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain
Call: ERC PROOF OF CONCEPT GRANTS2 (ERC-2022-POC2, 2022)
Start date: 2022-11-01
End date: 2024-04-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Improving the survival of patients with osteosarcoma has long proved challenging. Osteosarcoma is a rare bone cancer (less than 0.2% of all cancers). However, it affects mainly children and young adolescents. The standard therapy for osteosarcoma consists in the surgeon removing the entire tumor with negative margins (resection of larger areas of bone than the tumor itself), to ensure that no cancer cells are found at the edge of the tissue removed. This means that in some cases these surgeries associate limb amputation and even when it is not the case, most patients that undergo limb-sparing surgery need reconstructive surgery to regain limb function. The aim of TRANSFORMER is to bring closer to the market a solution that will allow to simultaneously treat bone cancer in absence of side effects while allowing bone regeneration. The product to be developed in TRANSFORMER puts together for the first time bone regeneration biomaterials with an innovative therapy for cancer that – in contrast to chemotherapy – up to now has shown no secondary effects: cold atmospheric plasma-treated hydrogels. The technology is protected by two PCT. TRANSFORMER value proposition: the product focused in in TRANSFORMER will have a double advantage for the patients and clinicians: it will be a local therapy that will allow simultaneous bone cancer treatment and bone regeneration. TRANSFORMER is structured along several objectives: (i) to preclinically validate the plasma-treated biocomposite as a potential therapy against bone cancer and towards bone regeneration, advancing the technology from TRL of 3 to 5, subsequently making it ready for clinical development and transfer to a spin-off or a third party company. (ii) To consolidate our IP position. (iii) To adapt the development roadmap to the regulatory requirements. (iv) To build a comprehensive business case for the exploitation of the technology and subsequent strategy for knowledge transfer.
PRostate cancer OMics Oriented inTErvention (PROMOTE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Greece,Austria,Portugal,Spain,Poland
Call: MSCA Doctoral Networks 2023 (HORIZON-MSCA-2023-DN-01, 2023)
Start date: 2024-09-01
End date: 2028-08-31
Duration (months): 48.0
Total project cost (EUR): 2604335.66
EU funding (EUR): 2049184.8
Participants: 15
Project status: SIGNED

PROMOTE focuses on multidisciplinary education of doctoral candidates (DCs) in -omics and artificial intelligence (AI) mediated intervention to improve clinical management of Prostate Cancer (PCa). PCa is the second most common malignancy, affecting ~1.3 million men every year worldwide. Tragically, there is a treatment paradox, as ~45% of PCa patients experience slow-growing cancer and are unlikely to progress rapidly, while PCa is not curable at advanced stage. Evidently, clinical management of PCa is not optimal, as patients which do not require treatment are over-treated, while for those that immediate actions are required, efficient treatment are still needed. To fill the above gaps, PROMOTE was formed to educate DCs in emerging -omics and AI technologies and deliver: a) novel non-invasive tools (based on biomarker- and AI- models) to guide intervention, and b) more efficient treatment options for advanced PCa (particularly metastatic) driven by molecular characterisation of the disease phenotypes. PROMOTE brings together 13 leading centers from different disciplines, including 3 SMEs, 4 university hospitals with clinical laboratories and 2 research institutes and 4 universities, closely collaborating with solid scientific background, as demonstrated by multiple publications. PROMOTE research builds on: i) available biobanks and -omics datasets within PROMOTE consortium, including >3000 urinary proteomics, >1100 imaging datasets paired with biopsy and pathology data, >350 paired RNA and proteomics urinary profiles, >100 tissue proteomics and ~300 phospho, proteo-genomic and transcriptomics profiles from public repositories, ii) established software and analytical protocols on -omics data integration, AI feature extraction and integration, systems biology, pathway enrichment, drug repurposing and in vitro testing, and iii) infrastructure to support hosting and training of DCs. Moreover, PROMOTE training programme has strong innovation and industrial focus.

Keywords: ai,omics,prostate cancer,systems biology
Transformational crossing system to prevent amputation and treat complex chronic total occlusions in critical limb ischemia (FASTWIRE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Ireland
Call: EIC Accelerator Open 2023 (HORIZON-EIC-2023-ACCELERATOR-01, 2023)
Start date: 2023-03-01
End date: 2025-03-31
Duration (months): 25.0
Total project cost (EUR): 3544625.0
EU funding (EUR): 2478175.0
Participants: 1
Project status: CLOSED

Critical limb Threatening ischemia (CLTI) is caused by chronic total occlusions (CTOs) in the arteries of the lower extremities. Left untreated, the complications of CLTI results in amputation of the affected limb. The prognosis for those diagnosed with CLTI is comparative to an aggressive cancer. At 1 year post diagnosis, 25% of patients will die and 30% had an amputation, 60% are dead by year 5 CTO is caused by the build-up and calcification of plaque inside the artery, blocking the artery and hardens over time and prevents the passage of a guidewire or therapy device through the vessel. Versono has designed and developed a solution to allow an endovascular surgeon to confidently cross 90% of occlusions within 10 mins This dedicated CTO guidewire uses an acoustic wave (ultrasound) to penetrate through the calcium/plaque and enable physicians to apply other treatments like stents, balloons or atherectomy devices to unblock the CTO and restore blood flow to the tissue downstream.

Keywords: ultrasound,chronic total occlusions,critcal limb ischemia,avoiding amputation,guidewire technology,medical device
Circuit Quantum Electrodynamic Spectroscope: a new superconducting microwave quantum sensor (cQEDscope)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Condensed Matter Physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2022-STG, 2022)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 1480000.0
EU funding (EUR): 1480000.0
Participants: 1
Project status: SIGNED

Superconductivity is a remarkable phase of matter which has advanced a wide variety of fields, including particle accelerators, biomedical imaging tools, and quantum computers. However, there are fundamental open questions about the nature of the superconducting state in many materials, with new ones being discovered every year. Understanding their structure can help unravel the dynamics of interacting many-body quantum systems, and lead to a next generation of technological innovations. Superconducting circuits are macroscopic tunable quantum devices which can interact strongly while maintaining high coherence, making them a leading quantum computing platform. These advantages also make them excellent quantum sensors, and as they are entirely superconductor-based and operate at microwave frequencies well below the gap energy of most materials, superconducting circuits are ideally suited for the exploration of novel superconductors. cQEDscope will utilize superconducting circuits to expand our understanding of superconductivity in three ways: 1) using strong coupling to kinetic inductance, we will probe the structure of the superconducting order parameter in micron-sized samples (such as flakes of layered materials), orders of magnitude below current techniques; 2) using nonlinearity, we will implement a microwave analogue of Raman spectroscopy, allowing us to probe a wide frequency range and observe collective modes within the superconducting phase; 3) using quantum coherence, our circuit will interact with the Higgs collective mode to create the first Higgs-polariton, a novel quantum system by itself and a new path to study the superconducting structure. In addition to our contribution to the understanding of novel superconductors, cQEDscope will also develop a new quantum sensing tool for material exploration, and a promising new class of hybrid superconducting circuits with potential quantum technology applications.

Keywords: superconducting circuits,quantum sensing,unconventional superconductivity,collective modes,microwave spectroscopy
TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION (FUN-HSC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Cell Biology, Development, Stem Cells and R egeneration
Panel description: For all organisms : Structure and function of the cell, cell -cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: United Kingdom,Spain
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 2265684.0
EU funding (EUR): 2265684.0
Participants: 2
Project status: SIGNED

Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have recently found broadened applications to gene and cell therapy, against other cancers, genetic, autoimmune, and infectious diseases. Nonetheless, practical limitations, such as donor-matching or insufficient cell number render these therapies unfeasible or unsuccessful for many patients. Attempts to overcome these limitations have been unable to create a reliable source of HSC for patients: while we can generate human HSC from pluripotent stem cells (PSC), they resemble early development stages, lacking the functional maturation hallmarks. FUN-HSC aims at identifying core and actionable maturation pathways for HSCs and at defining the contribution of coordinated gene expression by chromatin regulation, using a combination of functional and genetic screening technologies and high-throughput readouts in vitro and in vivo. HSC maturation occurs in the liver during fetal development and confers functional multilineage hematopoiesis ability throughout adulthood. Using single cell omics analysis of human embryonic and fetal tissues, we describe multiple gene programs changing during developmental HSC maturation. This study will lead to candidate cell-intrinsic and niche-dependent instructions, which will be dissected in the context of the fetal liver, by analyzing the cell compartments and their interactions and by combining novel organoid technologies with mouse xenografts to model the fetal liver environment. Ultimately, we aim to identify a strategy that mimics these pathways in vitro to bring the maturation stage of the PSC-derived HSC, to a robustly engraftable and clinically valuable HSC source. Harnessing new knowledge in human HSC biology, cutting-edge genetics and tissue technologies, FUN-HSC will provide great advances in the mission of making and maintaining HSCs in vitro, enabling their full therapeutic potential.

Keywords: single cell,hematopoietic stem cells,hematopoietic stem cell transplantation,crispra,crispri,sgrna screening,fetal liver,stem cell niche,epigenetics
European Training Program for Deconvolution of Multi-scale Cilia Function in Health and Disease by Integrating Machine Learning-AI Approaches. (Cilia-AI)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Netherlands,Denmark,Germany,France,Italy,Spain,United Kingdom
Call: MSCA Doctoral Networks 2023 (HORIZON-MSCA-2023-DN-01, 2023)
Start date: 2025-01-01
End date: 2028-12-31
Duration (months): 48.0
Total project cost (EUR): 3608186.4
EU funding (EUR): 3608186.4
Participants: 17
Project status: SIGNED

Cilia-AI will train a new generation of multidisciplinary biomedical researchers and entrepreneurs, and those specializing in emerging machine learning technologies, a subset of AI. The focus is the study of primary cilia, microtubule-based projections on cell surfaces that play a pivotal role in coordinating cellular signalling pathways during development and homeostasis of cells, tissues and organs. These tiny structures are essential for various physiological functions such as hearing, smell, respiration, excretion and reproduction. Dysfunctional cilia can lead to >35 severe human diseases known as ciliopathies, exhibiting diverse and overlapping phenotypes, affecting up to 1 in 400 people. To unravel the multi-level organisation and regulation of cilia in health and disease, Cilia-AI employs a multidisciplinary approach, integrating cutting edge technologies like structural biology, omics- and organoid technologies. Advanced imaging techniques, including super-resolution microscopy, cryo-electron tomography and expansion microscopy, will be used to generate high-resolution and versatile datasets. Processing such data requires sophisticated computational methods. Cilia-AI is at the forefront of implementing and developing machine learning approaches to decipher these high-content datasets and integrate diverse multidisciplinary data. Cilia-AI offers unparalleled training opportunities for 14 Doctoral Candidates (DCs) in both academic and industrial settings. The training involves individual research projects, secondments, and network-wide sessions. This training equips DCs with skills attractive to both industrial and academic sectors, enhancing their career prospects in these domains. Overall, Cilia-AI’s research and training activities contribute to advancing the understanding of cilia in health and disease while fostering a new generation of skilled professionals with broad competences.

Keywords: cilia,ciliopathies,machine learning,muli omics,structural biology,molecular disease mechanisms,therapeutic target discovery
Waste Avoidance Strategies for Environmental Sustainability (WASTEWISE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Fair, healthy and environmentally-friendly food systems from primary production to consumption
Action type: Research and Innovation actions
Countries involved: Italy,Finland,Romania,Sweden,Spain,Switzerland
Call: Preventing and reducing food waste to reduce environmental impacts and to help reach 2030 climate targets (HORIZON-CL6-2024-FARM2FORK-01, 2024)
Start date: 2024-11-01
End date: 2028-04-30
Duration (months): 42.0
Total project cost (EUR): 3425315.0
EU funding (EUR): 3425315.0
Participants: 9
Project status: SIGNED

Aligned with the priorities of the European Green Deal, and the Farm-to- Fork strategy, combating food waste stands as a cornerstone for fostering a fair, healthy and environmentally friendly food system. WASTEWISE has been conceived to design realistic pathways of food waste prevention and reduction to deliver co-benefits for climate change mitigation , biodiversity and circularity WASTEWISE employs a holistic, multi-actor approach across the food supply chain, to measure environmental impact of food waste prevention and reduction propose evident-based measures and drive systemic shifts for sustainable food consumption, poverty alleviation, and environmental sustainability in prioritized supply chains. The ambition of WASTEWISE is to deepen the existing knowledge concerning the real extent of environmental impacts that can be achieved through food waste prevention and reduction efforts, and how they can accelerate the progress towards EU’s climate targets. In doing so, WASTEWISE will analyse food waste data, develop reliable methods to assess environmental impacts, and conduct policy analysis, to inform evidence-based and realistic scenarios for food waste prevention and reduction. By these evidence-based insights and pragmatic scenarios, WASTEWISE equips policy makers with key information and recommendation and the instruments to accelerate progress towards climate targets. The WASTEWISE consortium comprises all relevant scientific and technical expertise spanning FW quantification, environmental impact assessment, innovation and policy advice. Supported by stakeholders through Multi-Actors Platforms (ministries, companies, associations, NGOs), it ensures inclusive engagement and dissemination of results, fostering broad uptake across cultural and socio-economic contexts.

Keywords: life cycle assessment,product environmental footprint,food waste prevention and reduction,rebound effect,environmental and social innovation,multi actor platform,circular approach